<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32045501</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>01</Month>
        <Day>29</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>01</Month>
        <Day>29</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1099-1077</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>35</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>Human psychopharmacology</Title>
          <ISOAbbreviation>Hum Psychopharmacol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Baclofen modulates cardiovascular responses to appetitive cues in treatment-seeking alcohol use disorder individuals.</ArticleTitle>
        <Pagination>
          <StartPage>e2722</StartPage>
          <MedlinePgn>e2722</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/hup.2722</ELocationID>
        <Abstract>
          <AbstractText Label="OBJECTIVE">To assess whether baclofen-treated alcohol dependent participants show different subjective and psychophysiological responses to appetitive cues during an alcohol cue reactivity task compared to placebo, and whether these responses are associated with prospective drinking outcomes.</AbstractText>
          <AbstractText Label="METHODS">Forty-two alcohol dependent participants (placebo: n = 12, low-dose baclofen [30 mg/day] n = 18, high-dose baclofen [75 mg/day]: n = 12) completed an alcohol cue reactivity task, whereby water and alcohol beverage cues were presented, with subsequent recovery periods, and subjective alcohol craving and psychophysiological indices (skin conductance; cardiovascular measures: heart rate, high-frequency heart rate variability) were recorded.</AbstractText>
          <AbstractText Label="RESULTS">High-dose baclofen-treated participants showed both overall cue reactivity to water and alcohol cues and greater recovery effects during recovery periods, revealed by high-frequency heart rate variability, when compared to low-dose- and placebo-treated participants. There were no medication effects on subjective craving. In high-dose baclofen participants only, there was a predictive effect of lower baseline heart rate variability and fewer post-test percentage of heavy drinking days.</AbstractText>
          <AbstractText Label="CONCLUSION">There was a dose-specific rescuing effect of high-dose baclofen on the dynamic modulation of cardiovascular responses to eliciting cues. Investigation of treatment responses using psychophysiological techniques may elucidate baclofen's mechanisms of action, and identify subgroups amenable to treatment.</AbstractText>
          <CopyrightInformation>© 2020 John Wiley &amp; Sons Ltd.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Logge</LastName>
            <ForeName>Warren B</ForeName>
            <Initials>WB</Initials>
            <Identifier Source="ORCID">0000-0003-0777-3033</Identifier>
            <AffiliationInfo>
              <Affiliation>Discipline of Addiction Medicine, Central Clinical School, Faculty of Medicine and Health, University of Sydney, New South Wales, Australia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Drug Health Services, Royal Prince Alfred Hospital, New South Wales, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Baillie</LastName>
            <ForeName>Andrew J</ForeName>
            <Initials>AJ</Initials>
            <AffiliationInfo>
              <Affiliation>Faculty of Health Sciences, University of Sydney, New South Wales, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Haber</LastName>
            <ForeName>Paul S</ForeName>
            <Initials>PS</Initials>
            <AffiliationInfo>
              <Affiliation>Discipline of Addiction Medicine, Central Clinical School, Faculty of Medicine and Health, University of Sydney, New South Wales, Australia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Drug Health Services, Royal Prince Alfred Hospital, New South Wales, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Morley</LastName>
            <ForeName>Kirsten C</ForeName>
            <Initials>KC</Initials>
            <AffiliationInfo>
              <Affiliation>Discipline of Addiction Medicine, Central Clinical School, Faculty of Medicine and Health, University of Sydney, New South Wales, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D018848">Controlled Clinical Trial</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>02</Month>
          <Day>11</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Hum Psychopharmacol</MedlineTA>
        <NlmUniqueID>8702539</NlmUniqueID>
        <ISSNLinking>0885-6222</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D058786">GABA-B Receptor Agonists</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>H789N3FKE8</RegistryNumber>
          <NameOfSubstance UI="D001418">Baclofen</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000437" MajorTopicYN="N">Alcoholism</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001418" MajorTopicYN="N">Baclofen</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D066249" MajorTopicYN="N">Craving</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003463" MajorTopicYN="N">Cues</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058786" MajorTopicYN="N">GABA-B Receptor Agonists</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005712" MajorTopicYN="N">Galvanic Skin Response</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006339" MajorTopicYN="N">Heart Rate</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">alcohol use disorder</Keyword>
        <Keyword MajorTopicYN="Y">baclofen</Keyword>
        <Keyword MajorTopicYN="Y">cue reactivity</Keyword>
        <Keyword MajorTopicYN="Y">heart rate variability</Keyword>
        <Keyword MajorTopicYN="Y">regulation</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>5</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2019</Year>
          <Month>11</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>1</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>2</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>2</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32045501</ArticleId>
        <ArticleId IdType="doi">10.1002/hup.2722</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>REFERENCES</Title>
        <Reference>
          <Citation>Addolorato, G., Caputo, F., Capristo, E., Domenicali, M., Bernardi, M., Janiri, L., … Gasbarrini, G. (2002). Baclofen efficacy in reducing alcohol craving and intake: A preliminary double-blind randomized controlled study. Alcohol and Alcoholism, 37(5), 504-508. https://doi.org/10.1093/alcalc/37.5.504</Citation>
        </Reference>
        <Reference>
          <Citation>Addolorato, G., Leggio, L., Ferrulli, A., Cardone, S., Vonghia, L., Mirijello, A., … Gasbarrini, G. (2007). Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: Randomised, double-blind controlled study. The Lancet, 370(9603), 1915-1922. https://doi.org/10.1016/S0140-6736(07)61814-5</Citation>
        </Reference>
        <Reference>
          <Citation>ADInstruments. (2012). Labchart Pro (Version 7.3.7). Bella Vista, Australia: ADInstruments.</Citation>
        </Reference>
        <Reference>
          <Citation>Agabio, R., Sinclair, J. M. A., Addolorato, G., Aubin, H.-J., Beraha, E. M., Caputo, F., … Leggio, L. (2018). Baclofen for the treatment of alcohol use disorder: The Cagliari statement. The Lancet Psychiatry, 5(12), 957-960. https://doi.org/10.1016/S2215-0366(18)30303-1</Citation>
        </Reference>
        <Reference>
          <Citation>Beck, A., Pelz, P., Lorenz, R. C., Charlet, K., Geisel, O., Heinz, A., … Müller, C. A. (2018). Effects of high-dose baclofen on cue reactivity in alcohol dependence: A randomized, placebo-controlled pharmaco-fMRI study. European Neuropsychopharmacology, 28, 1206-1216. https://doi.org/10.1016/j.euroneuro.2018.08.507</Citation>
        </Reference>
        <Reference>
          <Citation>Beraha, E. M., Salemink, E., Goudriaan, A. E., Bakker, A., de Jong, D., Smits, N., … Wiers, R. W. (2016). Efficacy and safety of high-dose baclofen for the treatment of alcohol dependence: A multicentre, randomised, double-blind controlled trial. European Neuropsychopharmacology, 26(12), 1950-1959. https://doi.org/10.1016/j.euroneuro.2016.10.006</Citation>
        </Reference>
        <Reference>
          <Citation>Biosignal Analysis and Medical Imaging Group. (2012). Kubios HRV (Version 2.2). Kuopio, Finland: Biosignal Analysis and Medical Imaging Group.</Citation>
        </Reference>
        <Reference>
          <Citation>Bohn, M. J., Krahn, D. D., &amp; Staehler, B. A. (1995). Development and initial validation of a measure of drinking urges in abstinent alcoholics. Alcoholism: Clinical and Experimental Research, 19(3), 600-606. https://doi.org/10.1111/j.1530-0277.1995.tb01554.x</Citation>
        </Reference>
        <Reference>
          <Citation>Carter, B. L., &amp; Tiffany, S. T. (1999). Meta-analysis of cue-reactivity in addiction research. Addiction, 94(3), 327-340. https://doi.org/10.1046/j.1360-0443.1999.9433273.x</Citation>
        </Reference>
        <Reference>
          <Citation>Chapleau, M. W., &amp; Sabharwal, R. (2011). Methods of assessing vagus nerve activity and reflexes. Heart Failure Reviews, 16(2), 109-127. https://doi.org/10.1007/s10741-010-9174-6</Citation>
        </Reference>
        <Reference>
          <Citation>Evans, S. M., &amp; Bisaga, A. (2009). Acute interaction of baclofen in combination with alcohol in heavy social drinkers. Alcoholism: Clinical and Experimental Research, 33(1), 19-30. https://doi.org/10.1111/j.1530-0277.2008.00805.x</Citation>
        </Reference>
        <Reference>
          <Citation>Farokhnia, M., Schwandt, M. L., Lee, M. R., Bollinger, J. W., Farinelli, L. A., Amodio, J. P., … Leggio, L. (2017). Biobehavioral effects of baclofen in anxious alcohol-dependent individuals: A randomized, double-blind, placebo-controlled, laboratory study. Translational Psychiatry, 7, e1108. https://doi.org/10.1038/tp.2017.71</Citation>
        </Reference>
        <Reference>
          <Citation>Flannery, B. A., Volpicelli, J. R., &amp; Pettinati, H. M. (1999). Psychometric properties of the Penn alcohol craving scale. Alcoholism: Clinical and Experimental Research, 23(8), 1289-1295. https://doi.org/10.1111/j.1530-0277.1999.tb04349.x</Citation>
        </Reference>
        <Reference>
          <Citation>Falk, D., Wang, X. Q., Liu, L., Fertig, J., Mattson, M, Ryan, M., … Litten, R.Z. (2010). Percentage of subjects with no heavy drinking days: evaluation as an efficacy endpoint for alcohol clinical trials. Alcoholism: Clinical and Experimental Research, 34, 2022-2034. https://doi:10.1111/j.1530-0277.2010.01290.x</Citation>
        </Reference>
        <Reference>
          <Citation>Garbutt, J. C., Kampov-Polevoy, A. B., Gallop, R., Kalka-Juhl, L., &amp; Flannery, B. A. (2010). Efficacy and safety of baclofen for alcohol dependence: A randomized, double-blind, placebo-controlled trial. Alcoholism: Clinical and Experimental Research, 34(11), 1849-1857. https://doi.org/10.1111/j.1530-0277.2010.01273.x</Citation>
        </Reference>
        <Reference>
          <Citation>Garland, E. L., Franken, I. H., &amp; Howard, M. O. (2012). Cue-elicited heart rate variability and attentional bias predict alcohol relapse following treatment. Psychopharmacology, 222(1), 17-26. https://doi.org/10.1007/s00213-011-2618-4</Citation>
        </Reference>
        <Reference>
          <Citation>Ingjaldsson, J. T., Laberg, J. C., &amp; Thayer, J. F. (2003). Reduced heart rate variability in chronic alcohol abuse: Relationship with negative mood, chronic thought suppression, and compulsive drinking. Biological Psychiatry, 54(12), 1427-1436. https://doi.org/10.1016/S0006-3223(02)01926-1</Citation>
        </Reference>
        <Reference>
          <Citation>Koob, G. F., &amp; Le Moal, M. (2008). Neurobiological mechanisms for opponent motivational processes in addiction. Philosophical Transactions of the Royal Society B: Biological Sciences, 363(1507), 3113-3123. https://doi.org/10.1098/rstb.2008.0094</Citation>
        </Reference>
        <Reference>
          <Citation>Laborde, S., Mosley, E., &amp; Thayer, J. F. (2017). Heart rate variability and cardiac vagal tone in psychophysiological research-Recommendations for experiment planning, data analysis, and data reporting. Frontiers in Psychology, 8(213). https://doi.org/10.3389/fpsyg.2017.00213</Citation>
        </Reference>
        <Reference>
          <Citation>Leggio, L., Zywiak, W. H., McGeary, J. E., Edwards, S., Fricchione, S. R., Shoaff, J. R., … Kenna, G. A. (2013). A human laboratory pilot study with baclofen in alcoholic individuals. Pharmacology Biochemistry and Behavior, 103(4), 784-791. https://doi.org/10.1016/j.pbb.2012.11.013</Citation>
        </Reference>
        <Reference>
          <Citation>Logge, W. B., Morley, K. C., Haber, P. S., &amp; Baillie, A. J. (2018). Executive functioning moderates responses to appetitive cues: A study in severe alcohol use disorder and alcoholic liver disease. Alcohol and Alcoholism, 54(1), 38-46. https://doi.org/10.1093/alcalc/agy083</Citation>
        </Reference>
        <Reference>
          <Citation>Logge, W. B., Morris, R. W., Baillie, A. J., Haber, P. S., &amp; Morley, K. C. (2019). Baclofen attenuates fMRI alcohol cue reactivity in treatment-seeking alcohol dependent individuals. Psychopharmacology. https://doi.org/10.1007/s00213-019-05192-5</Citation>
        </Reference>
        <Reference>
          <Citation>Malliani, A. (2005). Heart rate variability: From bench to bedside. European Journal of Internal Medicine, 16(1), 12-20. https://doi.org/10.1016/j.ejim.2004.06.016</Citation>
        </Reference>
        <Reference>
          <Citation>Miller, W. R., Tonigan, J. S., &amp; Longabaugh, R. (1995). The drinker inventory of consequences (DrInC): An instrument for assessing adverse consequences of alcohol abuse (Vol. 4). Rockville, MD: NIAAA.</Citation>
        </Reference>
        <Reference>
          <Citation>Monti, P. M., Binkoff, J. A., Abrams, D. B., Zwick, W. R., Nirenberg, T. D., &amp; Liepman, M. R. (1987). Reactivity of alcoholics and nonalcoholics to drinking cues. Journal of Abnormal Psychology, 96(2), 122-126.</Citation>
        </Reference>
        <Reference>
          <Citation>Morley, K. C., Baillie, A., Fraser, I., Furneaux-Bate, A., Dore, G., Roberts, M., … Haber, P. S. (2018). Baclofen in the treatment of alcohol dependence with or without liver disease: Multisite, randomised, double-blind, placebo-controlled trial. The British Journal of Psychiatry, 212(6), 362-369. https://doi.org/10.1192/bjp.2018.13</Citation>
        </Reference>
        <Reference>
          <Citation>Morley, K. C., Haber, P. S., Baillie, A., Leung, S., Addolorato, G., &amp; Leggio, L. (2014). Baclofen for the treatment of alcohol dependence and possible role of comorbid anxiety. Alcohol and Alcoholism, 49(6), 654-660. https://doi.org/10.1093/alcalc/agu062</Citation>
        </Reference>
        <Reference>
          <Citation>Morley, K. C., Leung, S., Baillie, A., &amp; Haber, P. S. (2013). The efficacy and biobehavioural basis of baclofen in the treatment of alcoholic liver disease (BacALD): Study protocol for a randomised controlled trial. Contemporary Clinical Trials, 36(2), 348-355. https://doi.org/10.1016/j.cct.2013.08.002</Citation>
        </Reference>
        <Reference>
          <Citation>Müller, C. A., Geisel, O., Pelz, P., Higl, V., Krüger, J., Stickel, A., … Heinz, A. (2015). High-dose baclofen for the treatment of alcohol dependence (BACLAD study): A randomized, placebo-controlled trial. European Neuropsychopharmacology, 25(8), 1167-1177. https://doi.org/10.1016/j.euroneuro.2015.04.002</Citation>
        </Reference>
        <Reference>
          <Citation>Naqvi, N. H., Ochsner, K. N., Kober, H., Kuerbis, A., Feng, T., Wall, M., &amp; Morgenstern, J. (2015). Cognitive regulation of craving in alcohol-dependent and social drinkers. Alcoholism: Clinical and Experimental Research, 39(2), 343-349. https://doi.org/10.1111/acer.12637</Citation>
        </Reference>
        <Reference>
          <Citation>Pierce, M., Sutterland, A., Beraha, E. M., Morley, K. C., &amp; van den Brink, W. (2018). Efficacy, tolerability, and safety of low-dose and high-dose baclofen in the treatment of alcohol dependence: A systematic review and meta-analysis. European Neuropsychopharmacology, 28(7), 795-806. https://doi.org/10.1016/j.euroneuro.2018.03.017</Citation>
        </Reference>
        <Reference>
          <Citation>Porges, S. W. (2007). The polyvagal perspective. Biological Psychology, 74(2), 116-143. https://doi.org/10.1016/j.biopsycho.2006.06.009</Citation>
        </Reference>
        <Reference>
          <Citation>Reid, M. S., Flammino, F., Starosta, A., Palamar, J., &amp; Franck, J. (2006). Physiological and subjective responding to alcohol cue exposure in alcoholics and control subjects: Evidence for appetitive responding. Journal of Neural Transmission, 113(10), 1519-1535. https://doi.org/10.1007/s00702-005-0439-5</Citation>
        </Reference>
        <Reference>
          <Citation>Reynaud, M., Aubin, H.-J., Trinquet, F., Zakine, B., Dano, C., Dematteis, M., … Detilleux, M. (2017). A randomized, placebo-controlled study of high-dose baclofen in alcohol-dependent patients-The ALPADIR study. Alcohol and Alcoholism, 52(4), 439-446. https://doi.org/10.1093/alcalc/agx030</Citation>
        </Reference>
        <Reference>
          <Citation>Skinner, H. A., &amp; Allen, B. A. (1982). Alcohol dependence syndrome: Measurement and validation. Journal of Abnormal Psychology, 91(3), 199-209.</Citation>
        </Reference>
        <Reference>
          <Citation>Sobell, L. C., &amp; Sobell, M. B. (1992). Timeline follow-back. In R. Z. Litten &amp; J. P. Allen (Eds.), Measuring alcohol consumption: Psychosocial and biochemical methods (pp. 41-72). Totowa, NJ: Humana Press.</Citation>
        </Reference>
        <Reference>
          <Citation>Sullivan, J. T., Sykora, K., Schneiderman, J., Naranjo, C. A., &amp; Sellers, E. M. (1989). Assessment of alcohol withdrawal: The revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). British Journal of Addiction, 84(11), 1353-1357.</Citation>
        </Reference>
        <Reference>
          <Citation>Tarvainen, M. P., Ranta-Aho, P. O., &amp; Karjalainen, P. A. (2002). An advanced detrending method with application to HRV analysis. IEEE Transactions on Biomedical Engineering, 49(2), 172-175.</Citation>
        </Reference>
        <Reference>
          <Citation>Thayer, J. F., Åhs, F., Fredrikson, M., Sollers, J. J., &amp; Wager, T. D. (2012). A meta-analysis of heart rate variability and neuroimaging studies: Implications for heart rate variability as a marker of stress and health. Neuroscience &amp; Biobehavioral Reviews, 36(2), 747-756. https://doi.org/10.1016/j.neubiorev.2011.11.009</Citation>
        </Reference>
        <Reference>
          <Citation>Thayer, J. F., &amp; Lane, R. D. (2009). Claude Bernard and the heart-brain connection: Further elaboration of a model of neurovisceral integration. Neuroscience &amp; Biobehavioral Reviews, 33(2), 81-88. https://doi.org/10.1016/j.neubiorev.2008.08.004</Citation>
        </Reference>
        <Reference>
          <Citation>World Health Organization. (1990). Alcohol dependence syndrome. In International statistical classification of diseases and related health problems (10th ed.). Retrieved from http://apps.who.int/classifications/icd10/browse/2010/en#/F10.2.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
